Table 2.

Histopathology diagnostics.

Gastric Pathologies
	Corpus			Antrum
Polymorphonuclear cell	15/55 (27.3%)			16/65 (24.6%)
Lymphoplasmocitar cell	47/55 (85.5%)			57/65 (87.7%)
Atrophy	19/55 (34.5%)			16/65 (24.6%)
Complete Metaplasia	4/55 (7.3%)	All Metaplasia	6/55 (10.9%)	19/65 (29.2%)	All Metaplasia	25/65 (38.5%)
Incomplete Metaplasia	2/55 (3.6%)			6/65 (9.2%)
Reduced Dysplasia	7/55 (12.7%)			13/65 (20%)
High Dysplasia	1/55 (1.8%)			2/65 (3.1%)
Hyperplasic Polyps	8/55 (14.5%)	All Polyps	12/55 (21.8%)	10/66 (15.2%)	All Polyps	15/66 (22.7%)
Adenomatous Polyps	0/55 (0%)			1/66 (1.5%)
Dysplasic Polyps	0/55 (0%)			1/66 (1.5%)
Inflammatory Polyps	4/55 (7.3%)			5/66 (7.6%)
Tumor	3/55 (5.5%)			2/66 (3%)
Acute/(Acute + Chronic)	28/72 (38.9%)
Giemsa	22/105 RUT positive (21%)